ADAR1‐HNRNPL‐Mediated CircCANX Decline Promotes Autophagy in Chronic Obstructive Pulmonary Disease

Abstract Chronic obstructive pulmonary disease (COPD) is a characteristic chronic airway inflammatory disease that worsens over time, however, there are currently limited clinical therapeutics to suspend its progression. Circular RNAs (circRNAs), which have emerged as functional regulators in variou...

Full description

Saved in:
Bibliographic Details
Main Authors: Ting‐Ting Chen, Yuan‐Yuan Wei, Jia‐Ying Kang, Da‐Wei Zhang, Jing‐Jing Ye, Xi‐Shi Sun, Mei Hong, Wen‐Ting Zhang, Hui‐Mei Wu, Zhen‐Xing Ding, Guang‐He Fei
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202414211
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Chronic obstructive pulmonary disease (COPD) is a characteristic chronic airway inflammatory disease that worsens over time, however, there are currently limited clinical therapeutics to suspend its progression. Circular RNAs (circRNAs), which have emerged as functional regulators in various diseases, including COPD, may server as new pharmacological targets in COPD. Here, it is identified a nuclear circRNA, circCANX, that is preferentially decreased in COPD. The linear splicing of CANX pre‐mRNA, enhanced by the ADAR1‐HNRNPL interaction, is responsible for the circCANX decline. Clinically, the higher circCANX expression is associated with a worse lung function index of FEV1/FVC among patients with COPD. CircCANX suppresses autophagy and stress granule (SG) formation to strengthen inflammation of COPD in vivo and in vitro. Mechanistically, circCANX recruits the tumor suppressor protein P53 (P53) mRNA and RNA helicase upstream frameshift 1 (UPF1) to form a ternary complex, which mediates P53 mRNA degradation through nonsense‐mediated mRNA decay (NMD) process. Together, this study reveals an important circCANX‐mediated regulatory mechanism in COPD, and provides new insights into the potential of circRNA‐based drug and biomarker development for COPD.
ISSN:2198-3844